8-KMaterial Agreements

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Aug 4, 2009)

Filed August 4, 2009For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. announced a significant amendment to its license, development, and commercialization agreement with Mitsubishi Tanabe Pharma Corporation, dated July 30, 2009. This amendment provides Vertex with an immediate cash infusion of $105.0 million, expected in the third quarter of 2009. Furthermore, Vertex is now eligible to receive additional milestone payments ranging from $15.0 million to $65.0 million in lieu of traditional royalties. This revised agreement grants Mitsubishi Tanabe Pharma Corporation a fully-paid license to commercialize telaprevir as part of a combination therapy for Hepatitis C Virus (HCV) infection in Japan and the Far East. It also includes rights for Mitsubishi Tanabe Pharma to manufacture telaprevir for sale in these specific regions. The deal signifies a strategic shift in how Vertex will monetize its telaprevir asset in this territory, focusing on upfront and milestone payments over future royalty streams.

Key Highlights

  • 1Vertex Pharmaceuticals amended its agreement with Mitsubishi Tanabe Pharma Corporation on July 30, 2009.
  • 2The company will receive $105.0 million in cash during the third quarter of 2009.
  • 3Vertex is eligible for additional milestone payments totaling between $15.0 million and $65.0 million.
  • 4These milestone payments will be received in lieu of royalties from sales in Japan and the Far East.
  • 5The amended agreement grants Mitsubishi Tanabe Pharma a fully-paid license to commercialize telaprevir in a combination regimen for HCV.
  • 6Mitsubishi Tanabe Pharma also gains rights to manufacture telaprevir for sale in Japan and the Far East.
  • 7This amendment represents a significant financial event for Vertex, providing immediate capital and potential future revenue.

Frequently Asked Questions

The primary financial impact is a $105.0 million cash payment expected in Q3 2009, along with eligibility for up to $65.0 million in additional milestone payments. This significantly boosts Vertex's immediate liquidity and potential future revenue.

Mitsubishi Tanabe Pharma gains a fully-paid license to commercialize telaprevir in a combination therapy for HCV in Japan and the Far East. They also secure the rights to manufacture telaprevir for sale in that region.

Instead of receiving ongoing royalties from sales in Japan and the Far East, Vertex will receive an upfront payment and potential milestone payments. This shifts the revenue recognition to be more immediate and event-driven rather than tied directly to sales volume over time.

Telaprevir is being developed for the treatment of Hepatitis C Virus (HCV) infection. Under this amended agreement, it will be commercialized as part of a combination regimen in Japan and the Far East.